跳至主要内容
临床试验/NCT02005133
NCT02005133终止不适用

A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics

Novartis Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 188 人开始时间: 2013年11月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
188
试验地点
1
主要终点
Frequency of aflibercept administration

研究概览

简要总结

To assess the use of aflibercept over a 2 year period in VEGF inhibitor naive and prior treated wet AMD patients managed in 'real wold' clinic settings.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age greater or equal to 50 years Active choroidal neovascularisation secondary to AMD in one or both eyes which in the opinion of the investigator will benefit from treatment with aflibercept Subject willing and able to provide informed consent

排除标准

  • Patients must not have had any prior use of either bevacizumab or aflibercept
  • Other protocol-defined inclusion/exclusion criteria may apply

结局指标

主要结局

Frequency of aflibercept administration

时间窗: Up to 1 year

To assess the frequency of clinic visits over a 1 year period in VEGF inhibitor naive wet AMD patients managed in 'real world' clinic settings.

次要结局

  • Change in central retinal thickness from baseline(Up to 2 years)
  • Frequency of clinic visits(Up to 1 year)
  • Changes in visual acuity from baseline(Up to 2 years)
  • Aflibercept Administration(Up to 2 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

A Prospective, Observational, Multicentre, 2 Year... | 临床试验